Over the last decade, the treatment for CLL has significantly advanced with agents targeting B-cell lymphoma 2 (BCL2), Bruton’s tyrosine kinase, and CD20. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.